Dayvigo (Lemborexant) Safety in Adults 65 and Older

Does lemborexant need a lower dose after age 65?

Lemborexant is a dual orexin receptor antagonist: it is presumed to work by blocking orexin A and orexin B at the OX1R and OX2R receptors and suppressing wake drive, and it is not a GABA-A drug, benzodiazepine or Z-drug [1].

The label's dosing section lists no age-based adjustment. The dose is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening, with a possible increase to a maximum of 10 mg based on clinical response and tolerability [1]. Lemborexant showed no clinically significant pharmacokinetic differences by age, sex, race or body mass index [1]. Its effective half-life is about 17 hours at 5 mg and 19 hours at 10 mg, with peak levels around 1 to 3 hours after dosing [1].

Two situations change the standard dose. Moderate hepatic impairment caps the dose at 5 mg, and severe hepatic impairment is not recommended [1]. A weak CYP3A inhibitor also caps the dose at 5 mg, while strong or moderate CYP3A inhibitors are to be avoided [1]. Taking the tablet with or soon after a meal can delay sleep onset; a high-fat meal reduced Cmax by 23% and delayed Tmax by 2 hours [1].

Which label warnings matter most after 65?

Falls. The label states that because Dayvigo can cause drowsiness, patients, particularly the elderly, are at a higher risk of falls [1].

Next-day impairment. Dayvigo is a CNS depressant that can impair daytime wakefulness even when used as prescribed, and those effects may persist in some patients for up to several days after discontinuation [1]. Driving ability was impaired in some subjects taking 10 mg, and the label says to caution patients taking 10 mg against next-day driving and other activities requiring complete mental alertness [1]. The risk of daytime impairment is increased if the drug is taken with less than a full night of sleep remaining or at a higher than recommended dose [1].

Additive sedation. Co-administration with other CNS depressants such as benzodiazepines, opioids, tricyclic antidepressants or alcohol increases the risk of CNS depression; the label says not to consume alcohol with Dayvigo and that using it with other insomnia drugs is not recommended [1]. In a drug interaction study, alcohol raised lemborexant Cmax and AUC and produced a numerically greater negative effect on postural stability and memory than alcohol alone when assessed 2 hours after dosing [1].

Other labeled events. Sleep paralysis (inability to move or speak for up to several minutes at sleep-wake transitions), hypnagogic and hypnopompic hallucinations, and cataplexy-like leg weakness lasting seconds to minutes can occur [1]. Complex sleep behaviors such as sleep-walking and sleep-driving have been reported with hypnotics such as Dayvigo; two events occurred in the trials, both at 10 mg, and the label says to discontinue the drug immediately if one occurs [1]. Suicidal ideation or any suicidal behavior assessed by questionnaire was reported in 0.3% of patients on 10 mg, 0.4% on 5 mg and 0.2% on placebo, and the label advises prescribing the lowest number of tablets feasible [1]. Dayvigo was studied in mild to severe obstructive sleep apnea and moderate to severe COPD in short-term trials, and the label says its effect on respiratory function should be considered in patients with compromised respiratory function [1].

What did the older-adult trial show?

SUNRISE 1 was a phase 3, randomized, double-blind, parallel-group, placebo- and active-controlled trial at 67 sites in North America and Europe. It enrolled 1,006 adults aged 55 and older with insomnia disorder (86.4% women, median age 63) and randomized them to placebo (n=208), zolpidem extended-release 6.25 mg (n=263), lemborexant 5 mg (n=266) or lemborexant 10 mg (n=269) for one month [2].

Against placebo, latency to persistent sleep on polysomnography gave a ratio of 0.77 with 5 mg and 0.72 with 10 mg, both P<.001; sleep efficiency rose 7.1% and 8.0% and wake after sleep onset fell 24.0 and 25.4 minutes [2]. In the second half of the night, wake after sleep onset was 6.7 minutes (5 mg) and 8.0 minutes (10 mg) lower than with zolpidem extended-release 6.25 mg [2].

What about longer treatment?

SUNRISE 2 randomized 949 adults aged 18 and older with insomnia to placebo, lemborexant 5 mg or 10 mg for a 6-month placebo-controlled period within a 12-month trial [4]. Patient-reported sleep onset latency, wake after sleep onset and sleep efficiency improved significantly versus placebo at month 6 and at most time points, most adverse events were mild or moderate, and the trial had a low rate of serious events and no deaths [4].

How common are the side effects?

The labeling reports adverse reaction rates from 1,418 adults aged 18 to 88 in two controlled trials [1]. In the first 30 days, somnolence occurred in 10% of patients on 10 mg, 7% on 5 mg and 1% on placebo; combined somnolence or fatigue in 9.6%, 6.9% and 1.3%; headache in 4.5%, 5.9% and 3.4%; and nightmares or abnormal dreams in 2.2%, 0.9% and 0.9% [1].

Discontinuation because of adverse reactions was 2.6% on 10 mg, 1.4% on 5 mg and 1.5% on placebo in the first 30 days, and 8.3%, 4.1% and 3.8% over 6 months, with somnolence, nightmares and palpitations the most common reasons over the 6-month period [1]. Sleep paralysis was reported in 1.6% of patients on 10 mg and 1.3% on 5 mg versus none on placebo, and hypnagogic hallucinations in 0.7% and 0.1% versus none [1].

Which interactions matter with a long medication list?

Strong CYP3A inhibitors (the label's examples are itraconazole and clarithromycin) and moderate ones (fluconazole, verapamil) increase lemborexant AUC and Cmax, and the label says to avoid concomitant use [1]. Weak inhibitors such as chlorzoxazone and ranitidine cap the lemborexant dose at 5 mg [1]. Strong or moderate CYP3A inducers (rifampin, carbamazepine and St. John's wort are the label's strong examples; bosentan, efavirenz, etravirine and modafinil the moderate ones) decrease lemborexant exposure and may reduce efficacy, so the label says to avoid them [1].

In the other direction, lemborexant decreases the AUC of CYP2B6 substrates such as bupropion and methadone, which may reduce their efficacy; the label says to monitor for adequate clinical response and that increasing the dose of the substrate may be considered [1].

Is it a controlled substance?

Yes. The label states that Dayvigo contains lemborexant, a Schedule IV controlled substance, and DEA placed lemborexant in Schedule IV by a rule published and effective April 7, 2020 [1][5][6]. On August 11, 2026, DEA published a proposed rule to move suvorexant, lemborexant and daridorexant to Schedule V; comments closed September 10, 2026, and no final rule had been published as of October 29, 2026, so lemborexant remains in Schedule IV [7].

In a human abuse potential study in 29 recreational sedative users, lemborexant 10, 20 and 30 mg produced drug-liking responses statistically similar to zolpidem 30 mg and suvorexant 40 mg and greater than placebo [1]. In animal studies and clinical trials, chronic administration did not produce withdrawal signs or symptoms on discontinuation, which the label says suggests it does not produce physical dependence [1].